Tempus AI's $1.5 billion acquisition of Personalis, announced July 20, 2026, looks prescient after Moderna and Merck reported positive Phase 3 results for mRNA-4157, a personalized cancer vaccine that…
Microsoft Research on August 4th spotlighted PRISM2, a multimodal pathology model developed by Paige and Microsoft researchers, trained on 2,350,518 whole-slide images from 685,507 specimens and about…
Tempus AI shares fell 7.74% to $48.41 on July 20, 2026, after the company agreed to acquire Personalis for about $1.5 billion, or $16.25 per share, with Personalis shares dropping 13.32% to $13.34. Th…
Tempus AI has agreed to acquire Personalis, Inc. for $1.5 billion, or $16.25 per share, gaining its NeXT Personal minimal residual disease blood test for cancer detection. The deal targets a $20 billi…
Tempus AI (TEM) has been identified by analysts as one of the top healthcare mid-cap artificial intelligence stocks. The company's position in the AI-driven healthcare sector has drawn positive attent…
H.C. Wainwright has reaffirmed its Buy rating on Tempus AI (TEM) following the company's strong revenue growth. The analyst's decision reflects confidence in Tempus AI's financial performance and mark…